AbCellera Biologics target raised to $14 from $9 by Stifel
ABCL•Stifel raised its target price for AbCellera Biologics to $14 from $9.
Related News
Deutsche Bank raises Fortune Brands Innovations target price to $48 from $41
FBIN•
BioNTech to acquire US FDA priority review voucher
SRRK•
BioNTech to buy FDA priority review voucher from Scholar Rock for $205 million
BNTX•
CalciMedica Q3 net loss narrows 78% to $1.7 million
CALC•
Scholar Rock posts first product revenue after ISEMBYLD launch
SRRK•